131 related articles for article (PubMed ID: 20513856)
1. An early improvement threshold to predict response and remission in first-episode schizophrenia.
Schennach-Wolff R; Seemüller FH; Mayr A; Maier W; Klingberg S; Heuser I; Klosterkötter J; Gastpar M; Häfner H; Sauer H; Schneider F; Gaebel W; Jäger M; Möller HJ; Riedel M
Br J Psychiatry; 2010 Jun; 196(6):460-6. PubMed ID: 20513856
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
3. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
4. Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol.
Riedel M; Mayr A; Seemüller F; Maier W; Klingberg S; Heuser I; Klosterkötter J; Gastpar M; Schmitt A; Sauer H; Schneider F; Gaebel W; Jäger M; Möller HJ; Schennach-Wolff R
World J Biol Psychiatry; 2012 Jan; 13(1):30-8. PubMed ID: 21568628
[TBL] [Abstract][Full Text] [Related]
5. Should early improvement be re-defined to better predict the maintenance of response in first-episode schizophrenia patients?
Schennach R; Riesbeck M; Mayr A; Seemüller F; Maier W; Klingberg S; Heuser I; Klosterkötter J; Gastpar M; Schmitt A; Sauer H; Schneider F; Jäger M; Wölwer W; Gaebel W; Möller HJ; Riedel M
Acta Psychiatr Scand; 2013 Jun; 127(6):474-81. PubMed ID: 22957829
[TBL] [Abstract][Full Text] [Related]
6. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
[TBL] [Abstract][Full Text] [Related]
7. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
[TBL] [Abstract][Full Text] [Related]
8. Finding Early Improvement Threshold to Predict Response After 8 Weeks of Treatment Using Risperidone in First-Episode Psychosis.
Subeesh V; Maheswari E; Singh H; Neha R; Mazhar F
J Clin Psychopharmacol; 2021 Jan/Feb 01; 41(1):58-61. PubMed ID: 33347025
[TBL] [Abstract][Full Text] [Related]
9. Early improvement in PANSS-30, PANSS-8, and PANSS-6 scores predicts ultimate response and remission during acute treatment of schizophrenia.
Lin CH; Lin HS; Lin SC; Kuo CC; Wang FC; Huang YH
Acta Psychiatr Scand; 2018 Feb; 137(2):98-108. PubMed ID: 29280500
[TBL] [Abstract][Full Text] [Related]
10. Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder.
Schennach-Wolff R; Meyer S; Seemüller F; Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Möller HJ; Riedel M
J Psychiatr Res; 2011 Dec; 45(12):1639-47. PubMed ID: 21862035
[TBL] [Abstract][Full Text] [Related]
11. Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program.
Leucht S; Zhao J
J Psychopharmacol; 2014 Apr; 28(4):387-94. PubMed ID: 24429222
[TBL] [Abstract][Full Text] [Related]
12. Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia.
Docherty JP; Baker RA; Eudicone J; Mathew S; Marcus RN; McQuade RD; Mankoski R
Schizophr Res; 2010 Jul; 120(1-3):199-203. PubMed ID: 20547037
[TBL] [Abstract][Full Text] [Related]
13. Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study.
Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Degner D; Buchkremer G; Gastpar M; Möller HJ; Riedel M
Eur Psychiatry; 2009 Dec; 24(8):501-6. PubMed ID: 19559572
[TBL] [Abstract][Full Text] [Related]
14. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
[TBL] [Abstract][Full Text] [Related]
15. Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates.
Emsley R; Rabinowitz J; Medori R;
Schizophr Res; 2007 Jan; 89(1-3):129-39. PubMed ID: 17095194
[TBL] [Abstract][Full Text] [Related]
16. Remission in first-episode psychosis: predictor variables and symptom improvement patterns.
Emsley R; Oosthuizen PP; Kidd M; Koen L; Niehaus DJ; Turner HJ
J Clin Psychiatry; 2006 Nov; 67(11):1707-12. PubMed ID: 17196049
[TBL] [Abstract][Full Text] [Related]
17. Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
Anghelescu IG; Janssens L; Kent J; de Boer P; Tritsmans L; Daly EJ; van Nueten L; Schmidt ME
Eur Neuropsychopharmacol; 2013 Sep; 23(9):1043-50. PubMed ID: 22995972
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST).
Boter H; Peuskens J; Libiger J; Fleischhacker WW; Davidson M; Galderisi S; Kahn RS;
Schizophr Res; 2009 Dec; 115(2-3):97-103. PubMed ID: 19819114
[TBL] [Abstract][Full Text] [Related]
19. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis.
Stauffer VL; Case M; Kinon BJ; Conley R; Ascher-Svanum H; Kollack-Walker S; Kane J; McEvoy J; Lieberman J
Psychiatry Res; 2011 May; 187(1-2):42-8. PubMed ID: 21168920
[TBL] [Abstract][Full Text] [Related]
20. Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies.
O'Gorman C; Kapur S; Kolluri S; Kane J
Hum Psychopharmacol; 2011; 26(4-5):282-90. PubMed ID: 21638329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
